Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26


Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end-stage renal disease.

Assing K, Nielsen C, Jakobsen M, Scholze A, Nybo M, Soerensen G, Mortensen S, Vejen K, Barington T, Bistrup C.

Immun Inflamm Dis. 2016 May 25;4(2):225-234. eCollection 2016 Jun.


Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease.

Heier CR, Fiorillo AA, Chaisson E, Gordish-Dressman H, Hathout Y, Damsker JM, Hoffman EP, Conklin LS.

Clin Transl Gastroenterol. 2016 Sep 15;7(9):e192. doi: 10.1038/ctg.2016.49.


Phenotype and function of CXCR5+CD45RA-CD4+ T cells were altered in HBV-related hepatocellular carcinoma and elevated serum CXCL13 predicted better prognosis.

Duan Z, Gao J, Zhang L, Liang H, Huang X, Xu Q, Zhang Y, Shen T, Lu F.

Oncotarget. 2015 Dec 29;6(42):44239-53. doi: 10.18632/oncotarget.6235.


Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis.

Donahoe M, Valentine VG, Chien N, Gibson KF, Raval JS, Saul M, Xue J, Zhang Y, Duncan SR.

PLoS One. 2015 Jun 17;10(6):e0127771. doi: 10.1371/journal.pone.0127771. eCollection 2015. Erratum in: PLoS One. 2015;10(7):e0133684.


CXCL13 antibody for the treatment of autoimmune disorders.

Klimatcheva E, Pandina T, Reilly C, Torno S, Bussler H, Scrivens M, Jonason A, Mallow C, Doherty M, Paris M, Smith ES, Zauderer M.

BMC Immunol. 2015 Feb 12;16:6. doi: 10.1186/s12865-015-0068-1.


Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study).

Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, Tang MT, Grogan JL, Hsieh F, Davis JC.

Arthritis Res Ther. 2014 Oct 30;16(5):467. doi: 10.1186/s13075-014-0467-3.


CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic 'window of opportunity'.

Greisen SR, Schelde KK, Rasmussen TK, Kragstrup TW, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Deleuran B, Hvid M.

Arthritis Res Ther. 2014 Sep 24;16(5):434. doi: 10.1186/s13075-014-0434-z.


Endometrial CXCL13 expression is cycle regulated in humans and aberrantly expressed in humans and Rhesus macaques with endometriosis.

Franasiak JM, Burns KA, Slayden O, Yuan L, Fritz MA, Korach KS, Lessey BA, Young SL.

Reprod Sci. 2015 Apr;22(4):442-51. doi: 10.1177/1933719114542011. Epub 2014 Jul 16.


Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels.

Jones JD, Hamilton BJ, Challener GJ, de Brum-Fernandes AJ, Cossette P, Liang P, Masetto A, Ménard HA, Carrier N, Boyle DL, Rosengren S, Boire G, Rigby WF.

Arthritis Res Ther. 2014 Apr 25;16(2):R103. doi: 10.1186/ar4552.


C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis.

Vuga LJ, Tedrow JR, Pandit KV, Tan J, Kass DJ, Xue J, Chandra D, Leader JK, Gibson KF, Kaminski N, Sciurba FC, Duncan SR.

Am J Respir Crit Care Med. 2014 Apr 15;189(8):966-74. doi: 10.1164/rccm.201309-1592OC.


Low serum levels of myeloid progenitor inhibitory factor-1 predict good response to methotrexate in rheumatoid arthritis.

Dhir V, Sandhu A, Gupta N, Dhawan V, Sharma S, Sharma A.

ISRN Inflamm. 2013 Dec 24;2013:460469. doi: 10.1155/2013/460469. eCollection 2013 Dec 24.


CXCL13 is elevated in Sjögren's syndrome in mice and humans and is implicated in disease pathogenesis.

Kramer JM, Klimatcheva E, Rothstein TL.

J Leukoc Biol. 2013 Nov;94(5):1079-89. doi: 10.1189/jlb.0113036. Epub 2013 Jul 31.


Development of a multi-biomarker disease activity test for rheumatoid arthritis.

Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan KA, Turner M, Sutton C, Smith DR, Haney DJ, Chernoff D, Hesterberg LK, Carulli JP, Taylor PC, Shadick NA, Weinblatt ME, Curtis JR.

PLoS One. 2013 Apr 9;8(4):e60635. doi: 10.1371/journal.pone.0060635. Print 2013. Erratum in: PLoS One. 2014;9(6):e99812.


Mechanistic biomarkers for clinical decision making in rheumatic diseases.

Robinson WH, Lindstrom TM, Cheung RK, Sokolove J.

Nat Rev Rheumatol. 2013 May;9(5):267-76. doi: 10.1038/nrrheum.2013.14. Epub 2013 Feb 19. Review.


Bone formation and resorption are both increased in experimental autoimmune arthritis.

Keller KK, Thomsen JS, Stengaard-Pedersen K, Dagnæs-Hansen F, Nyengaard JR, Hauge EM.

PLoS One. 2012;7(12):e53034. doi: 10.1371/journal.pone.0053034. Epub 2012 Dec 27.


Assessment of synovitis to predict bone erosions in rheumatoid arthritis.

Bugatti S, Manzo A, Caporali R, Montecucco C.

Ther Adv Musculoskelet Dis. 2012 Aug;4(4):235-44. doi: 10.1177/1759720X12453092.


Pre-analytical effects of blood sampling and handling in quantitative immunoassays for rheumatoid arthritis.

Zhao X, Qureshi F, Eastman PS, Manning WC, Alexander C, Robinson WH, Hesterberg LK.

J Immunol Methods. 2012 Apr 30;378(1-2):72-80. doi: 10.1016/j.jim.2012.02.007. Epub 2012 Feb 17.


Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs.

Bugatti S, Manzo A, Benaglio F, Klersy C, Vitolo B, Todoerti M, Sakellariou G, Montecucco C, Caporali R.

Arthritis Res Ther. 2012 Feb 15;14(1):R34. doi: 10.1186/ar3742.


Immunopathological roles of cytokines, chemokines, signaling molecules, and pattern-recognition receptors in systemic lupus erythematosus.

Yu SL, Kuan WP, Wong CK, Li EK, Tam LS.

Clin Dev Immunol. 2012;2012:715190. doi: 10.1155/2012/715190. Epub 2012 Jan 23. Review.


Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial.

Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC.

Arthritis Res Ther. 2012 Jan 8;14(1):R6. doi: 10.1186/ar3554.

Supplemental Content

Support Center